You are here

P&T News

January 22

ASP0113 missed key endpoints in phase 3 trial

January 19

32 states experience high activity levels in week ending January 13

January 18

Overall survival rose by about one-third in a European study
Risk of death drops 21% in relapsed or refractory patients
Prostate cancer drug earns $1 billion a year for Janssen
Median PFS more than doubles in CELESTIAL trial
Health systems’ plan is a response to shortages and price hikes

January 16

Analysts predict peak sales of about $8.2 billion by 2020
New pilot program to evaluate disclosure of clinical study reports
New label includes data on three additional EGFR mutations: L861Q, G719X, and S768I
Vaccine was previously approved for patients older than 3 years of age
Head-to-head study compared Cosentyx and Stelara

January 12

Pharmacists call shortage of small-volume parenteral solutions "severe"
First PARP inhibitor to receive FDA approval for use beyond ovarian cancer

January 11

CMS issues guidance allowing states to propose programs
Low levels of the mineral are common among women
Society for Healthcare Epidemiology of America provides guidance
Lipocine defends drug’s safety and efficacy

January 9

DOJ is investigating drug-makers’ financial support of patient-assistance charities
The treatment is being jointly developed by Eisai and Merck

Pages